568 related articles for article (PubMed ID: 22815633)
1. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Zhu L; Zhang C; Chuck RS
Mol Vis; 2012; 18():1803-12. PubMed ID: 22815633
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model.
Zhu L; Shen J; Zhang C; Park CY; Kohanim S; Yew M; Parker JS; Chuck RS
Mol Vis; 2009; 15():250-8. PubMed ID: 19190733
[TBL] [Abstract][Full Text] [Related]
3. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Lekhanont K; Park CY; Smith JA; Combs JC; Preechawat P; Suwan-Apichon O; Rangsin R; Chuck RS
J Ocul Pharmacol Ther; 2007 Feb; 23(1):27-34. PubMed ID: 17341147
[TBL] [Abstract][Full Text] [Related]
4. Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye.
Hongyok T; Chae JJ; Shin YJ; Na D; Li L; Chuck RS
Arch Ophthalmol; 2009 Apr; 127(4):525-32. PubMed ID: 19365035
[TBL] [Abstract][Full Text] [Related]
5. Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model.
Park CY; Zhuang W; Lekhanont K; Zhang C; Cano M; Lee WS; Gehlbach PL; Chuck RS
Mol Vis; 2007 Nov; 13():2222-32. PubMed ID: 18087241
[TBL] [Abstract][Full Text] [Related]
6. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model.
Lekhanont K; Leyngold IM; Suwan-Apichon O; Rangsin R; Chuck RS
Cornea; 2007 Jan; 26(1):84-9. PubMed ID: 17198019
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Suwan-apichon O; Rizen M; Rangsin R; Herretes S; Reyes JM; Lekhanont K; Chuck RS
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):133-9. PubMed ID: 16384954
[TBL] [Abstract][Full Text] [Related]
8. Effect of 0.025% FK-506 eyedrops on botulinum toxin B-induced mouse dry eye.
Lin BW; Chen MZ; Fan SX; Chuck RS; Zhou SY
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):45-53. PubMed ID: 25491293
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 0.025% FK-506, 0.05% Cyclosporin A, and 0.3% Sodium Hyaluronate Eye Drops for the Treatment of Botulinum Toxin B-Induced Mouse Dry Eye.
Lin BW; Huang WL; Wang L; Chen ZM
J Ocul Pharmacol Ther; 2018 Nov; 34(9):633-641. PubMed ID: 30227093
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of topical adiponectin in a mouse model of desiccating stress-induced dry eye.
Li Z; Woo JM; Chung SW; Kwon MY; Choi JS; Oh HJ; Yoon KC
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):155-62. PubMed ID: 23211823
[TBL] [Abstract][Full Text] [Related]
11. Cevimeline-induced anti-inflammatory effect through upregulations of mucins in the ocular surface of a dry eye mouse model.
Kim CE; Kim YJ; Hwang MW; Park YJ; Yang J
Biomed Pharmacother; 2021 Jul; 139():111571. PubMed ID: 33857915
[TBL] [Abstract][Full Text] [Related]
12. Effects of silk fibroin in murine dry eye.
Kim CE; Lee JH; Yeon YK; Park CH; Yang J
Sci Rep; 2017 Mar; 7():44364. PubMed ID: 28281688
[TBL] [Abstract][Full Text] [Related]
13. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial.
Pinto-Fraga J; López-Miguel A; González-García MJ; Fernández I; López-de-la-Rosa A; Enríquez-de-Salamanca A; Stern ME; Calonge M
Ophthalmology; 2016 Jan; 123(1):141-53. PubMed ID: 26520171
[TBL] [Abstract][Full Text] [Related]
14. Effects of eye drops containing a mixture of 3% diquafosol sodium and tocopherol acetate (vitamin E) on the ocular surface of murine dry eye.
Li L; Jin R; Li Y; Yoon HS; Yoon HJ; Yoon KC
Cutan Ocul Toxicol; 2021 Dec; 40(4):350-358. PubMed ID: 34496685
[TBL] [Abstract][Full Text] [Related]
15. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
Lekhanont K; Park CY; Combs JC; Suwan-Apichon O; Rangsin R; Chuck RS
J Ocul Pharmacol Ther; 2007 Feb; 23(1):83-8. PubMed ID: 17341156
[TBL] [Abstract][Full Text] [Related]
16. Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome.
Jiang D; Liu X; Hu J
Eye (Lond); 2017 Dec; 31(12):1724-1732. PubMed ID: 28643798
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of topical infliximab in a mouse model of experimental dry eye.
Li Z; Choi W; Oh HJ; Yoon KC
Cornea; 2012 Nov; 31 Suppl 1():S25-31. PubMed ID: 23038030
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effects of Pyranoprofen on the mouse dry eye induced by topical medication of Benzalkonium Chloride].
He H; Liu ZG; Lin ZR; Liu XC; He H; Xiao QG
Zhonghua Yan Ke Za Zhi; 2012 Jan; 48(1):33-40. PubMed ID: 22490914
[TBL] [Abstract][Full Text] [Related]
19. Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model.
Kim DW; Lee SH; Ku SK; Cho SH; Cho SW; Yoon GH; Hwang HS; Park J; Eum WS; Kwon OS; Choi SY
BMB Rep; 2013 Feb; 46(2):124-9. PubMed ID: 23433117
[TBL] [Abstract][Full Text] [Related]
20. Amniotic membrane extract ameliorates benzalkonium chloride-induced dry eye in a murine model.
Xiao X; Luo P; Zhao H; Chen J; He H; Xu Y; Lin Z; Zhou Y; Xu J; Liu Z
Exp Eye Res; 2013 Oct; 115():31-40. PubMed ID: 23792171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
